Streetbeat News

Analyst Ratings

HUBS

HubSpot (NYSE:HUBS) has received positive analyst ratings in the last quarter, with 15 out of 18 analysts being bullish or somewhat bullish. The average price target is $590.94, indicating an upside from the current price of $550.45. The average price target has increased by 16.46% over the past month.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 9:00 pm

ZI

Over the past 3 months, 20 analysts have published their opinion on ZoomInfo Technologies (NASDAQ:ZI) stock. The average price target is $27.5, implying an upside from the current price of $18.11. This average has decreased by 13.52% from the previous average price target of $31.80.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 9:00 pm

SPCE

John Hempton, founder and CIO at Bronte Capital, criticized Chamath Palihapitiya, known as the 'SPAC King', over his past dealings. The criticism was in response to a tweet by Palihapitiya praising 'disagreeable' individuals in the start-up space. Hempton's comments refer to Palihapitiya's past SPAC activities, including the public listing of Virgin Galactic Holdings Inc (NYSE:SPCE), which left some investors with significant losses. Despite the collapse of numerous SPACs he championed, Palihapitiya remains unrepentant and continues to find investments.

Portfolio Pulse from AJ Fabino

September 05, 2023 | 8:59 pm

ORCL

A significant investor has taken a bearish stance on Oracle (NYSE:ORCL), with 66% of spotted trades being bearish. The whales have been targeting a price range from $90.0 to $175.0 for Oracle over the last 3 months. The price of ORCL is up 2.52% at $123.98, and RSI indicators suggest it may be approaching overbought. UBS and Barclays have upgraded their actions to Buy and Overweight respectively, with price targets of $140 and $150.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 8:30 pm

CRWD

A significant bullish stance has been taken on CrowdStrike Holdings (NASDAQ:CRWD) as evidenced by unusual options activity. The overall sentiment of these big-money traders is split between 62% bullish and 37% bearish. The whales have been targeting a price range from $110.0 to $200.0 for CrowdStrike Holdings over the last 3 months. The price of CRWD is up 2.6% at $165.43. Analysts have mixed opinions with price targets ranging from $153 to $235.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 8:16 pm

JNJ

A significant bearish stance has been taken on Johnson & Johnson (NYSE:JNJ) by a large investor or institution, as evidenced by unusual options trades. The sentiment among these big-money traders is 100% bearish. The targeted price range for JNJ over the last 3 months has been $155.0 to $210.0. Analysts from Cantor Fitzgerald and Morgan Stanley have given JNJ an Overweight and Equal-Weight rating respectively, with price targets of $215 and $172.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 8:15 pm

PXD

A significant bullish stance has been taken on Pioneer Natural Resources (NYSE:PXD) by a large investor or institution, as evidenced by unusual options activity. The sentiment among these big-money traders is split between 53% bullish and 46% bearish. The whales have been targeting a price range from $200.0 to $300.0 for PXD over the last 3 months. Analysts' price targets range from $230 to $265. The stock is currently trading at $243.03, up 1.34%.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 8:15 pm

AVAV

AeroVironment reported Q1 earnings of $1.00 per share, beating the analyst consensus estimate of $0.40 by 150%. The company also reported quarterly sales of $152.30 million, surpassing the analyst consensus estimate of $137.24 million by 10.97%. This represents a 1100% increase in earnings and a 40.35% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 8:12 pm

GTLB

GitLab (NASDAQ:GTLB) reported Q2 earnings of $0.01 per share, beating the analyst consensus estimate of $(0.03) by 133.33%. The company also reported quarterly sales of $139.58 million, surpassing the analyst consensus estimate of $129.67 million by 7.64%. This represents a 106.67% increase in earnings and a 38.14% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 8:08 pm

ASND

Ascendis Pharma reported Q2 earnings per share (EPS) of $(2.35), beating the analyst consensus estimate of $(2.68) by 12.16%. This is a 50.9% decrease from the same period last year. The company also reported quarterly sales of $51.66 million, surpassing the analyst consensus estimate of $41.73 million by 23.80%. This represents a 686.94% increase from the same period last year.

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 8:06 pm